Kiniksa Pharmaceuticals International (KNSA) Q1 2025 earnings summary

Executive summary

• ARCALYST Q1 2025 net product revenue reached $137.8 million, up 75% year-over-year, driven by increased prescriber base, longer treatment duration, and Medicare Part D changes.

• Net income for Q1 2025 was $8.5 million, reversing a net loss of $17.7 million in Q1 2024, supported by strong ARCALYST sales and milestone payments.

• Ended Q1 2025 with $268.3 million in cash, cash equivalents, and short-term investments, supporting ongoing operations and investments.

• Marked the fourth anniversary of FDA approval for ARCALYST in recurrent pericarditis, with expanding adoption and high payer approval rates.

• Advanced clinical portfolio includes KPL-387, with a Phase 2/3 trial in recurrent pericarditis set to initiate mid-2025.

Financial highlights

• Q1 2025 total revenue was $137.8 million, compared to $79.9 million in Q1 2024.

• Net income reached $8.5 million in Q1 2025, compared to a net loss of $17.7 million in Q1 2024.

• Operating expenses for Q1 2025 were $124.5 million, up from $96.4 million in Q1 2024, mainly due to higher collaboration, cost of goods sold, and SG&A.

• ARCALYST collaboration profit rose 118% year-over-year to $87.6 million in Q1 2025.

• Cash, cash equivalents, and short-term investments totaled $268.3 million as of March 31, 2025, with no debt.

Outlook and guidance

• 2025 ARCALYST net product revenue guidance raised to $590–$605 million, reflecting robust Q1 performance and commercial momentum.

• On track to initiate Phase 2/3 clinical trial for KPL-387 in recurrent pericarditis mid-2025, with Phase 2 data expected in the second half of 2026.

• Current operating plan expected to remain cash flow positive on an annual basis.